OphthalmoPharma’s current own pharmaceutical product pipeline is focused on the development of innovative drugs for Dry Eye and Glaucoma. 

Moreover, OphthalmoPharma's solubilisation and drug delivery platform can be used for several compounds in ophthalmology. These compounds can be selected in partnership with interested parties.

Thanks to its strong ability to source, secure and develop outstanding technologies in the field, the Company has assembled a rich pipeline of potential compounds for AMD, Uveitis and other indications available for co-development with industrial partners. These other projects can be sourced for and developed with partners and are not listed below.